At the time of the April 2019 CR Rennie said“This capital raise...

At the time of the April 2019 CR Rennie said
“This capital raise puts us in a privileged position whereby we are not boxed into a deal. We’ve got the funding to run the Phase III trial ourselves so we are not in a desperate rush to get a partner. We have the optionality of continuing to run the trial or we can partner.”

So, no to what you asked.

In any case they will run out of cash, so there is less optionality now than before, to do something about funding.
A good question to ask at the webinar, unfortunately i have a medical appointment so i hope someone asks about cash burn.

FWIW i would prefer a deal on MPS if that allows funding through to iPPS trials completion.

Back then, April 2019, on the original milestones, an end trials valuation of 10% penetration in the US alone and a revenue-based outlook of only 4.5% yielded a share price of at least $24.
Why would you partner iPPS for less?
See https://hotcopper.com.au/posts/56378072/single
IMO DYOR